Cargando…

From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure

Imatinib is a targeted cancer therapy that has significantly improved the care of patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). However, it has been shown that the recommended dosages of imatinib are associated with trough plasma concentration (Cmin) lower t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goutelle, Sylvain, Guidi, Monia, Gotta, Verena, Csajka, Chantal, Buclin, Thierry, Widmer, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142039/ https://www.ncbi.nlm.nih.gov/pubmed/37111566 http://dx.doi.org/10.3390/pharmaceutics15041081

Ejemplares similares

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
por: Buclin, Thierry, et al.
Publicado: (2020)

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
por: Briki, Myriam, et al.
Publicado: (2023)

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
por: Widmer, N, et al.
Publicado: (2008)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Tobramycin exposure from active calcium sulfate bone graft substitute
por: Livio, Françoise, et al.
Publicado: (2014)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children
por: Guidi, Monia, et al.
Publicado: (2019)

Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation
por: Terrier, Jean, et al.
Publicado: (2022)

Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
por: Staehli Hodel, Eva Maria, et al.
Publicado: (2013)

Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control
por: Courlet, Perrine, et al.
Publicado: (2022)

Biases affecting injected doses of an experimental drug during clinical trials
por: Perrottet, Nancy, et al.
Publicado: (2016)

Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy
por: Buclin, Thierry, et al.
Publicado: (2011)

Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial
por: Sottas, Oriane, et al.
Publicado: (2019)

Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy
por: Barceló, Catalina, et al.
Publicado: (2020)

Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre
por: Jermini, Mégane, et al.
Publicado: (2019)

Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study
por: Thoueille, Paul, et al.
Publicado: (2023)

Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
por: Dao, Kim, et al.
Publicado: (2020)

Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin
por: Heitzmann, Justine, et al.
Publicado: (2022)

Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
por: Thoueille, Paul, et al.
Publicado: (2023)

Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study
por: Bartelink, Imke H., et al.
Publicado: (2021)

Precision oncology- the future of personalized cancer medicine?
por: Bode, Ann M., et al.
Publicado: (2017)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
por: Katsumata, Ryo, et al.
Publicado: (2023)

Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy
por: Udden, S. M. Nashir, et al.
Publicado: (2023)

Correction to: Innovative radiation oncology Together—Precise, Personalized, Human
por: Krug, David, et al.
Publicado: (2021)

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
por: Bandiera, Carole, et al.
Publicado: (2023)

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
por: Gaspar, Frédéric, et al.
Publicado: (2023)

Dose-dependent severe cutaneous reactions to imatinib
por: Ugurel, S, et al.
Publicado: (2003)

Personal Cancer Genome Reporter: variant interpretation report for precision oncology
por: Nakken, Sigve, et al.
Publicado: (2018)

Innovative radiation oncology Together – Precise, Personalized, Human: Vision 2030 for radiotherapy & radiation oncology in Germany
por: Krug, David, et al.
Publicado: (2021)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology
por: Raufaste-Cazavieille, Virgile, et al.
Publicado: (2022)

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis
por: Jiang, Xuehui, et al.
Publicado: (2023)

Future paradigms for precision oncology
por: Klement, Giannoula Lakka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u0fn1dmj5ptivutca1polpcurj